VERI-LONG phase IIa trial of vericiguat
Charité Fatigue Center · 2023 · Charité and ClinicalTrials.gov
Indexed 2026-11-12.
Reported findings and study design
No measured outcomes in the accessed disclosure
Double-blind parallel comparison of vericiguat and placebo. The protocol escalated from 2.5 to 10 mg and used SF-36 physical function as its primary endpoint.
Dose, route and schedule
Double-blind parallel comparison of vericiguat and placebo. The protocol escalated from 2.5 to 10 mg and used SF-36 physical function as its primary endpoint.
Protocol source ↗ · Original source
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Results availability | The trial site and linked registry provided the protocol. No verified efficacy results were available in those records. |
The population includes participants with and without ME/CFS criteria. ClinicalTrials.gov identifier NCT05697640.
Source for these results ↗ · Reviewed 2026-11-12
For research and education. Consult a qualified clinician for medical advice.
Study limitations and source details
Study limitations
- The population includes participants with and without ME/CFS criteria. ClinicalTrials.gov identifier NCT05697640.
Related publications may cover the same research program or participants.
Source access
Double-blind parallel comparison of vericiguat and placebo. The protocol escalated from 2.5 to 10 mg and used SF-36 physical function as its primary endpoint.
Source reviewed 2026-11-12.
Source type: Trial registration
Citation and original source
Original source: Charité Fatigue Center. VERI-LONG phase IIa trial of vericiguat Charité and ClinicalTrials.gov 2023.
Molekul research summary: https://molekul.io/research/vericiguat-veri-long-protocol. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry